Drug Development Research · 1989 · 34 citations · 29 references
MedicinePharmacologyPharmacotherapyInflammationPain ManagementPain MedicineAnalgesic PharmacologyAnti-inflammatory PharmacologyDrug-receptor InteractionsInflammation PharmacologyPeptide Drug DiscoveryReceptor PharmacologyAnalgesic Anti-inflammatory PharmacologyB Cell Receptor AgonistsB Cell Receptor AntagonistsChronic Tissue InjuryIn Vivo StudiesPeptide Medicinal Chemistry
Abstract In vitro and in vivo studies of the actions of various antagonists and agonists of bradykinin (BK) B 1 and B 2 receptors have been reviewed and analyzed. It seems apparent that certain B 2 ‐antagonists, such as [Thi 5,8 ,D‐Phe 7 ]‐BK and D‐Arg 0 ‐[Hyp 3 ,Thi 5,8 ,D‐Phe 7 ]‐BK will serve as valuable model substances for developing new anti‐inflammatory/analgesic drugs. Further development of B 1 ‐antagonists, based on modifications of the structure of des‐Arg 9 ,[Leu 8 ]‐BK, or combined B 1 /B 2 ‐antagonists might be useful in controlling disease states involving chronic tissue injury and/or prolonged vasopasm.
29
Competitive antagonists of bradykinin
Raymond J. Vavrek · Peptides · 1985 · 468 citations
Philip C. Anderson · Journal of the American Academy of Dermatology · 1984 · 337 citations · Full text